Αναζήτηση Δραστικών

DOXORUBICIN

ATC

Εμπορικές Ονομασίες

  • CAELYX
    Μορφές: C/S.SOL.IN
  • ADRIBLASTINA
    Μορφές: PS.INJ.SOL
    Μορφές: PD.INJ.SOL
    Μορφές: INJ.SOL
  • DRUGBANK - Doxorubicin
  • indication:

    For the treatment of Koposi's sarcome connected to AIDS.

  • pharmacology:

  • mechanism:

    Doxorubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action: Doxorubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes.

  • toxicity:

    LD<sub>50</sub>=21800 ug/kg (rat, subcutaneous)

  • absorprion:

  • halflife:

    55 hours

  • roouteelimination:

    Plasma clearance is in the range 324 to 809 mL/min/m2 and is predominately by metabolism and biliary excretion.

  • volumedistribution:

  • clearance:

    * 324-809 mL/min/m2 * 1088 mL/min/m2 [Men] * 433 mL/min/m2 [Women] * 1540 mL/min/m2 [children greater than 2 years of age receiving administration of 10 to 75 mg/m2 doses] * 813 mL/min/m2 [infants younger than 2 years of age receiving administration of 10 to 75 mg/m2 doses]